Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/32696

Title:	Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study)
Authors:	Hartung, H-P Comi, G. Arnold, D. L. Boyko, A. N. Havrdova, E. K. Inshasi, J. S. McCombe, P. Nakamura, K. Oreja-Guevara, C. Pelletier, D. Pozzilli, C. Selmaj, K. W. Scott, T. F. Chung, L. Daizadeh, N. Afsar, S. VAN WIJMEERSCH, Bart
Issue Date:	2020
Publisher:	SAGE PUBLICATIONS LTD
Source:	MULTIPLE SCLEROSIS JOURNAL, 26 (9) , p. NP60 -NP61
Document URI:	http://hdl.handle.net/1942/32696
ISI #:	WOS:000556862300071
Category:	M
Type:	Journal Contribution
Appears in Collections:	Research publications

Check